Background. Immune responses are somewhat suppressed in immune privileged sites, including the testes, which provide a preexisting opportunity to prolong allograft survival. Previous studies have shown that intratesticular islet allografts enjoy extended survival even without any immunosuppression. However, it is unknown if testicular immune privilege can be exploited to prolong the survival of a solid allograft, including the skin, because it is impractical to implant a solid tissue in human testes. Methods. To immunize recipient mice, splenocytes from BALB/c mice were injected into the testis of C57BL/6 recipients 1 week before skin transplantation. CD8 + CD122+ and CD4 + FoxP3+ regulatory T [Treg] cells were quantified by fluorescence-activated cell sorting. Results. Although donor-antigen inoculation alone did not delay skin allograft rejection, it significantly extended the allograft survival when combined with CD40/CD40L or B7/CD28 costimulatory blockade and further induced long-term skin allograft acceptance when both costimulatory pathways were blocked. Similarly, donor-antigen inoculation suppressed alloreactive T cell proliferation in draining lymph nodes of skin recipients in the presence of the same costimulatory blockade. Interestingly, donorantigen inoculation via intratesticular injection increased CD8 + CD122+, but not CD4 + FoxP3+, Treg numbers after transplantation. However, both CD8 + CD122+ and CD4 + CD25+ Treg cells induced by donor-antigen inoculation and the costimulatory blockade were more potent in suppression than that induced without the inoculation. Depletion of CD8+ or CD25+ T cells largely abrogated long-term skin allograft survival induced by donor-antigen inoculation and the costimulatory blockade. Conclusions. Intratesticular inoculation with donor antigens promotes long-term skin allograft survival induced by conventional costimulatory blockade via the induction of both CD8 + CD122+ and CD4 + CD25+ Treg cells.
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Background. Immune responses are somewhat suppressed in immune privileged sites, including the testes, which provide a preexisting opportunity to prolong allograft survival. Previous studies have shown that intratesticular islet allografts enjoy extended survival even without any immunosuppression. However, it is unknown if testicular immune privilege can be exploited to prolong the survival of a solid allograft, including the skin, because it is impractical to implant a solid tissue in human testes. Methods. To immunize recipient mice, splenocytes from BALB/c mice were injected into the testis of C57BL/6 recipients 1 week before skin transplantation. CD8 + CD122+ and CD4 + FoxP3+ regulatory T [Treg] cells were quantified by fluorescence-activated cell sorting. Results. Although donor-antigen inoculation alone did not delay skin allograft rejection, it significantly extended the allograft survival when combined with CD40/CD40L or B7/CD28 costimulatory blockade and further induced long-term skin allograft acceptance when both costimulatory pathways were blocked. Similarly, donor-antigen inoculation suppressed alloreactive T cell proliferation in draining lymph nodes of skin recipients in the presence of the same costimulatory blockade. Interestingly, donorantigen inoculation via intratesticular injection increased CD8 + CD122+, but not CD4 + FoxP3+, Treg numbers after transplantation. However, both CD8 + CD122+ and CD4 + CD25+ Treg cells induced by donor-antigen inoculation and the costimulatory blockade were more potent in suppression than that induced without the inoculation. Depletion of CD8+ or CD25+ T cells largely abrogated long-term skin allograft survival induced by donor-antigen inoculation and the costimulatory blockade. Conclusions. Intratesticular inoculation with donor antigens promotes long-term skin allograft survival induced by conventional costimulatory blockade via the induction of both CD8 + CD122+ and CD4 + CD25+ Treg cells. T here are some tissues or organs where immune responses are subdued. This phenomenon is referred to as "immune privilege." For instance, survival of allografts has been prolonged in the testis of small animals without additional immunosuppression. [1] [2] [3] [4] The mechanisms responsible for immune privilege are not very clear. At the beginning, it was thought that immune privilege is caused by "immunological ignorance" due to the lack of the lymphatic drainage in immune privileged organs and existence of a physical blood-tissue barrier. 5 It is now known that foreign antigens in privileged organs can still cause antigen-specific immune responses. 6 Studies have also shown that ocular expression of Fas ligand (FasL) plays a role in the formation of its immune privilege via induction of Fas-positive inflammatory cell death 7 whereas testicular Sertoli cells also express FasL that helps suppress allograft rejection. 8 Cotransplantation of Sertoli cells and islet cells to the liver induced long-term islet allograft survival even in the absence of immunosuppression. 9 Recent studies exhibited dual roles of FasL in the immune privilege, 10, 11 because transgenic expression of FasL on islet cells resulted in a faster rejection of islet grafts. [12] [13] [14] Constitutive expression of PD-L1 contributed to testicular immune privilege 15 whereas natural killer T cells were also involved in the immune privilege of the eye. 16, 17 Moreover, local TGF-β expression was reportedly necessary for the immune privilege, 18, 19 whereas immune responses in the eye were skewed toward Th2 responses. 6, 20 Furthermore, IL-12/IL-35 common subunit p35 also contributed to the testicular immune privilege, 21 whereas rat resident testicular macrophages constitutively produced interleukin-10, 22 which likely played an important role in testicular immune privilege.
Although cellular allotransplantation in the testis could work in some situations, recent studies demonstrated that intratesticular islet transplantation did not delay islet allograft rejection 23 and that intratesticular islet allografts were rejected once cyclosporine was withdrawn, 24 suggesting that directly intratesticular islet transplantation may not be a good option. Especially, it is not at all practical to transplant large numbers of islets in human testes. However, we feel that immune privileged sites can still be used to facilitate allograft survival or tolerance. We speculate that long-term allograft survival in a nonprivileged conventional site, such as the skin, can be induced via donor-specific immunization in an immune privileged site of recipients before transplantation, which could "exhaust" alloimmunity due to the nature of immune privilege.
In this study, we investigated the survival of a skin allograft in a nonprivileged site after donor-antigen inoculation in the testes of recipient mice. We found that donor-antigen in the testes significantly prolonged skin allograft survival induced by CD40L blockade (MR1) or CTLA4-Ig, whereas treatments with both MR1 and CTLA4-Ig plus the inoculation resulted in long-term skin allograft acceptance. The donorantigen inoculation in recipient mice generated more CD8 + CD122+, but not CD4 + FoxP3+, regulatory T (Treg) cells whereas both Treg cells induced by the inoculation and costimulatory blockade were more potent in suppression than control Treg cells. These findings revealed new mechanisms underlying testicular immune privilege and demonstrated that an immunologically privileged site could be an excellent location for preemptive immunization before transplantation, instead of an implanting site.
MATERIALS AND METHODS

Mice
Wild-type BALB/c mice and C57BL/6 mice were purchased from Vital River (a branch of Charles River Company, Beijing, China). All mice were housed in a specific pathogen-free environment.
All of the animal protocols were approved by the Institutional Animal Care and Use Committee of Third Military Medical University.
Skin Transplantation
Skin donors were 7-to 8-week-old BALB/c, whereas recipients were 7-to 8-week-old C57BL/6 mice. Full thickness trunk skin was transplanted into a dorsal flank area of recipient mice. Skin rejection was defined as greater than 90% of graft necrosis.
In Vivo Treatments of Mice
To immunize recipient mice, 5 Â 10 6 splenocytes from BALB/c mice were injected into the testis of C57BL/6 recipient mice 1 week before skin transplantation. To block T cell costimulation and suppress alloimmune responses, B6 mice were injected intraperitoneally with MR1 (anti-CD40L Ab) and/or CTLA4-Ig (BioExpress, West Lebanon, NH) for 0.2 mg on days 0, 2, 4, and 6 after transplantation. To deplete CD8+ or CD25+ T cells in recipient mice, depleting anti-CD8 mAb (Bio X Cell, West Lebanon, NH), anti-CD25 mAb (PC61), or isotype Ab (Rat IgG2b) was administered at 0.2 mg on days 0, 3, and 6 after transplantation. CD8 + CD122+ or CD4 + CD25+ Treg cells were mostly depleted (~80%) by the depleting Abs but not isotype control Ab (data not shown).
Immunohistochemistry
The tissues of skin allografts were fixed, embedded in paraffin, and cut in 5-μm sections, which were then dried up at 55°C, deparaffinized in Xylen, followed by the dehydration via graded concentrations of the alcohol. The peroxidase activities were blocked by 3% H 2 0 2 . The sections then were incubated with antimouse CD3 mAb (Abcam, Cambridge, UK) at 4°C for 12 hours. Sections were finally colored with 3′3′-diaminobenzidene (Sigma) and counterstained by hematoxylin after incubation with the horseradish peroxidase-antimouse IgG.
FACS Analyses
One week or 2 weeks after transplantation, draining lymph node (LN) and spleen cells were isolated as described previously. 25, 26 For CD8 + CD122+ cells, they were stained with anti-CD8-PE and anti-CD122-fluorescein isothiocyanate (FITC) (BD Biosciences). For CD4 + FoxP3+ Treg cells, cells were first stained for a surface marker with anti-CD4-FITC Ab, and then intracellular markers with anti-FoxP3-PE mAb (eBioscience) using intracellular staining fixation and permeabilization kit (eBioscience). CD8 + CD122+ or CD4 + FoxP3+ Treg cells were quantified by a FACSCalibur (BD Biosciences).
Analysis of In Vivo T cell Proliferation by the 5-Bromo-2′-Deoxyuridine Labeling
Mice were immunized with donor splenocytes seven days before transplantation. Recipient mice were pulsed intraperitoneally with 0.8 mg of 5-bromo-2′-deoxyuridine (BrdU) (Sigma-Aldrich) 7 days after allogeneic skin transplantation. One more day later, draining LN cells were isolated and stained with anti-CD3-PE Ab (BD Biosciences). Cells then were fixed in 70% ethanol, followed by 1% paraformaldehyde, and incubated with 50 Units/mL of DNase I (Sigma-Aldrich). Finally, cells were stained with anti-BrdU-FITC Ab (BD Biosciences) and analyzed by the FACSCalibur (BD Biosciences).
Analysis of In Vitro Treg Cell Suppression of T cell Proliferation by [ 3 H]-Thymidine Uptake
Mice were immunized with donor splenocytes 7 days before transplantation. Two weeks after skin transplantation and treatments with conventional costimulatory blockade, splenocytes of B6 recipient mice were isolated and CD4 + CD25 + or CD8 + CD122+ Treg cells were purified using cell-sorter FACSAria (BD Biosciences). Their purity after cell sorting was typically over 95%. They were cultured without or with nylonwood-enriched T cells derived from naïve B6 mice in the 96-well plates in complete RPMI 1640 medium (10% fetal calf serum, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin). The ratios of Treg to T responder were 1:8 and 1:16, respectively. Irradiated BALB/c splenocytes were applied to the culture to serve as both alloantigens and antigen-presenting cells. Cells were pulsed with [ 3 H]-Thymidine for the last 6 hours before harvesting and analysis. Ninety-six hours after the cell culture, cells were harvested and analyzed by the Scintillation counter (PerkinElmer, Meriden, CT).
Methods of Statistical Analyses
Comparisons of the mean were conducted using analysis of variance. Analyses of allograft survival were performed using Kaplan-Meier method, mainly log-rank test. All of the analyses were performed using Prism6 software (GraphPad Software, La Jolla, CA). Data were represented as mean ± SD. P values less than 0.05 were considered statistically significant.
RESULTS
Immunization With Donor Splenocytes in the Testis of Recipient Mice Promotes Long-Term Skin Allograft Survival Induced by Conventional Costimulatory Blockade
Given that testicular immune privilege prolongs survival of cellular allograft in the testes but that it is impractical to implant islet or other cellular allografts in human testes, we tested whether immunization with donor cells or alloantigens in the testis of recipient mice would also extend the survival of skin allografts from the similar donors. Recipient mice were immunized with donor splenocytes via testicular injection 1 week before allogeneic skin transplantation and were treated with MR1 and/or CTLA4-Ig. As shown in Figure 1A , we found that testicular immunization alone did not significantly alter skin allograft rejection (median survival time [MST] = 11 vs 12 days; n = 7; P > 0.05). However, testicular immunization prolonged skin allograft survival in the presence of either CTLA4-Ig (MST = 32 vs 16 days; n = 7-8; P < 0.05) or MR1 (MST = 35 vs 18 days; n = 8; P < 0.05). FIGURE 1. Intratesticular immunization with donor splenocytes pretransplantation prolongs skin allograft survival induced by costimulatory blockade. B6 recipient mice were immunized with Balb/c donor splenocytes via intratesticular injection 1 week before skin transplantation and were treated with MR1 and/or CTLA4-Ig on days 0, 2, 4, and 6 after transplantation (A). As controls, recipient mice were also immunized with plain PBS via intratesticular injection or immunized with donor splenocytes via IIP with or without MR1 and/or CTLA4-Ig (B) ( # P > 0.05 and *P < 0.05). A representative of accepted skin allograft was shown in an immunized recipient treated with MR1 + CTLA4-Ig eight weeks after transplantation (C) while a skin allograft was acutely rejected in a control recipient two weeks after transplantation (D). Also shown were immunohistochemical staining for CD3 on paraffin embedded section of rejected skin allografts from a control (E), immunized (F) or MR1 + CTLA4-Igtreated recipient (G). Ten weeks after transplantation, a skin allograft from a recipient treated with both immunization and MR1 + CTLA4-Ig was still accepted without CD3 expression and cellular infiltration (H). (Magnification: Â400). IIP indicates i.p. injection.
Although, as expected, MR1 plus CTLA4-Ig dramatically prolonged skin allograft survival (MST = 71 vs 12 days; n = 7-8; P < 0.05), the immunization induced long-term skin allograft survival in recipient mice treated with both MR1 and CTLA4-Ig, with all grafts surviving for more than 90 days ( Figure 1A ). As controls, isotype Abs did not significantly alter allograft survival (data not shown). On the other hand, immunization with donor splenocytes intraperitoneally, instead of testicular injection, did not significantly affect allograft survival time when compared to nonimmunized recipients with or without MR1/CTLA4-Ig ( Figures 1A and B) . Representatives of accepted and rejected skin allografts were also shown ( Figures 1C and D) . Immunohistochemical staining revealed CD3 expression by rejected skin allografts of a control ( Figure 1E ), immunized ( Figure 1F ), or MR1+ CTLA4-Ig-treated recipient ( Figure 1G ), but no CD3 expression in a recipient that was both immunized and treated with MR1+ CTLA4-Ig ( Figure 1H ) 10 weeks after transplantation.
Immunization With Donor Antigens in the Testis of Skin Recipients Pretransplantation Enhances the Suppression of T Cell Proliferation by Costimulatory Blockade Posttransplantation
Recipient mice were immunized with donor splenocytes via testicular injection 1 week before allogeneic skin transplantation. Seven days after allogeneic skin transplantation and treatments with the costimulatory blockade, draining LN cells were isolated and analyzed for CD3+ T cell proliferation by the BrdU labeling. As shown in Figures 2A and B , the immunization alone did not change alloreactive T cell proliferation after transplantation (%BrdU+: 43 ± 2.8 vs 46 ± 3.5, P > 0.05). However, it reduced T cell proliferation in the presence of MR1 (%BrdU+: 22 ± 2.2 vs 33 ± 2.7, CD4 + CD25 + FoxP3+ Treg cells play a key role in maintaining immune tolerance to both self-antigens and foreign antigens by suppressing conventional T cell responses. They also suppress autoimmunity and allograft rejection in animal models. [27] [28] [29] [30] [31] [32] On the other hand, increasing evidence has shown that CD8 + CD122+ T cells are Treg cells that regulate conventional T cell homeostasis and activation [33] [34] [35] [36] [37] [38] and control both autoimmunity 39, 40 and alloimmunity. 41 However, it is unclear whether those Treg cells were involved in longterm allograft survival in this model. To answer this question, B6 recipient mice were immunized with Balb/c donor splenocytes via testicular injection 1 week before transplantation with Balb/c skin. One and 2 weeks after transplantation, CD4 + FoxP3+ Treg cells from draining LNs and spleens were stained and enumerated by FACS analyses. As shown in Figure 3 , the numbers of CD4 + FoxP3+ Treg cells per LN or spleen after intratesticular inoculation were comparable to that without inoculation in either presence or absence of MR1 and/or CTLA4-Ig (all P > 0.05), suggesting that donor-antigen inoculation via intratesticular injection does not further promote CD4 + FoxP3+ Treg generation. In contrast, the numbers of CD8 + CD122+ Treg cells per LN were significantly increased with intratesticular inoculation compared to those without the inoculation, either in the presence or absence of MR1 and/or CTLA4-Ig (all P < 0.05), 1 or 2 weeks after transplantation (Figure 4) . However, the numbers of CD8 + CD122+ Treg cells in the spleen were increased with intratesticular inoculation only in MR1-treated (7.3 ± 0.4 vs 5.5 ± 0.5, P < 0.05) or MR1 + CTLA4-Ig-treated group (9.2 ± 0.7 vs 6.9 ± 0.5, P < 0.05), but not in untreated (P > 0.05) or CTLA4-Ig-treated group (P > 0.05). As controls, inoculation via intraperitoneal injection did not significantly alter CD8 + CD122+ Treg numbers in the same setting (data not shown). These findings suggest that intratesticular inoculation with donor antigens before transplantation increases CD8 + CD122+, but not CD4 + FoxP3+, Treg numbers, especially in the presence of conventional costimulatory blockade. Although donor-antigen inoculation via intratesticular injection and costimulatory blockade induced CD8 + CD122+ Treg cells, it is unclear whether long-term skin allograft acceptance in this model is dependent on these induced Treg cells. To test this possibility, recipient mice again were immunized with donor splenocytes via testicular injection 1 week before allogeneic skin transplantation and treated with MR1 and CTLA4-Ig. As shown in Figure 6 , depletion of either CD8+ or CD25+ T cells in donor-antigen inoculated and MR1 + CTLA4-Ig-treated recipient mice largely abrogated long-term skin allograft survival, whereas all skin allografts in inoculated MR1 + CTLA4-Ig group survived for more than 90 days. Isotype control for depleting Abs did not shorten allograft survival induced by the inoculation plus MR1 + CTLA4-Ig. As a result, there was no difference in skin allograft survival between MR1 + CTLA4-Ig-alone group and donor-antigen inoculated MR1 + CTLA4-Ig plus depleting anti-CD8 Ab group.
DISCUSSION
Using an allogeneic skin transplant model and donorantigen inoculation method via intratesticular injection, we found that donor-antigen inoculation, instead of direct transplantation, in the testis of recipient mice prolonged skin allograft survival induced by conventional T cell costimulatory blockade. Donor-antigen inoculation extended skin allograft survival when combined with CD40/CD40L or B7/CD28 costimulatory blockade and induced long-term allograft acceptance when both costimulatory pathways were blocked. Similarly, donor-antigen inoculation suppressed the proliferation of alloreactive T cells in draining LNs of skin recipient mice in the presence of the same costimulatory blockade. Donor-antigen inoculation via intratesticular injection generated more CD8 + CD122+, but not CD4 + FoxP3+, Treg cells, whereas CD8 + CD122+ or CD4 + CD25+ Treg cells induced by donor-antigen inoculation and costimulatory blockade were more potent in suppression than those induced without the inoculation. These studies revealed new mechanisms of testicular immune privilege.
Previous studies have shown the prolonged survival of islet allograft transplanted in the testis of rodents without any treatment with immunosuppressive agents. [2] [3] [4] However, it has also been reported that intratesticular islet transplantation does not necessarily prolong allograft survival. 23 Instead, intratesticular islet allografts were rejected upon withdrawal of cyclosporine. 24 The temperature in testicular environment should also be a general concern for cellular allograft survival. Finally, it is impractical to implant large numbers of cellular allografts in human testes. Therefore, it is very limited to use immune privileged sites for accommodating cellular grafts due to their unique locations and limited sizes. Therefore, they have not been widely viewed as clinically useful. However, our findings suggest that testes can be used as a location for immunization with donor alloantigens before transplantation with the same donor organs/ tissues. This will significantly improve outcomes of transplantation in nonimmune privileged locations. Thus, they may be used to induce long-term allograft acceptance by simply providing a space for preemptive immunization rather than just a grafting site. This study could have implications for clinical transplantation. However, it remains to be determined if this immunization in testes with donor splenocytes causes local inflammation or other major side effects, including infertility and graft-versus-host diseases. We expect that it will cause a transient inflammation in testes and that these donor splenocytes are cleared in testes of wild-type mice within 2 to 4 weeks. It is unlikely that donor splenocytes injected into the testes of immune-competent wild-type animals would result in graft-versus-host diseases because even systemic administration of donor-specific splenocyte transfusion has not been reported to cause GVHD in wild-type animals. Nevertheless, these issues need to be thoroughly addressed before this strategy can be considered for clinical transplantation.
CD4 + CD25 + FoxP3+ Treg cells play an essential role in maintaining immune tolerance to both self-antigens and foreign antigens by suppressing conventional T cell responses. [42] [43] [44] Previous studies have shown that intratesticular islet transplantation induces antigen-specific CD4 + CD25 + FoxP3+ Treg cells that are essential for maintaining transplantation tolerance. 45 Others have also demonstrated that ovarian carcinoma promotes the immune privilege by recruiting CD4 + CD25+ Treg cells to the tumors 46 and that testicular Sertoli cells sustain de novo generation of CD4 + FoxP3+ Treg cells in vitro. 47 Here we found that intratesticular donor-antigen inoculation does not increase CD4 + FoxP3+ Treg numbers in LNs and spleens. The reasons for this discrepancy remain to be defined. Perhaps, donor splenocytes inoculated via intratesticular injection, unlike intratesticular islet allografts, do not provide a strong allogeneic stimulation sufficient for a significant increase in CD4 + FoxP3+ Treg numbers. It is also possible that the absence of an increase in the Treg numbers in LNs and spleens is because of their localization to skin allografts. However, we found that CD4 + CD25+ Treg cells generated by intratesticular donor-antigen inoculation are more potent in suppression than control Treg cells, suggesting that CD4 + CD25+ Treg cells generated in this setting may consist of more antigen-specific ones.
Mounting evidence has demonstrated that CD8 + CD122+ T cells are a new subset of Treg cells that maintain T cell homeostasis, suppress conventional T cell responsiveness, [33] [34] [35] [36] [37] [38] and regulate both autoimmunity and alloimmunity. 39, 40 They were actually memory Treg cells 48 that were more potent in the suppression of allograft rejection than conventional CD4 + CD25 + FoxP3+ Treg cells. 41 Interestingly, CD122 is the β subunit of IL-2 receptor on T cells, whereas CD25 is the α subunit of the same receptor, 44 suggesting that both units of the IL-2 receptor participate in Treg-mediated suppression. We found that intratesticular donor-antigen inoculation and costimulatory blockade of CD40/CD40L and B7/CD28 pathways increase CD8 + CD122+ but not CD4 + CD25+ Treg numbers. The mechanisms responsible for the increased numbers of CD8 + CD122+, but not CD4 + FoxP3+, Treg cells by testicular immune privilege remain to be defined. However, it is generally accepted that CD8+ T cells proliferate or expand more rapidly than their CD4+ counterparts. Previous studies have shown that CD8 + CD122+ Treg cells indeed undergo faster homeostatic proliferation than their CD4 + CD25 + FoxP3+ counterparts. 41 It is also unknown why the costimulatory blockade is required for the induction of CD8 + CD122+ Treg cells in this model. Here we speculate that the testicular immune privilege promotes homeostatic proliferation of T cells in vivo due to Fas-mediated effector T cell death in testes whereas costimulatory blockade suppresses expansion of conventional T cells but not memory-like CD8 + CD122+ Treg cells, which are relatively resistant to the costimulatory blockade.
We found that joint blockade of CD40/CD40L and B7/ CD28 costimulatory pathways induced CD8 + CD122+ Treg cells and dramatically prolonged skin allograft survival. Importantly, intratesticular inoculation with donor antigens and blocking both costimulatory pathways synergistically induced long-term skin allograft survival through further induction of CD8 + CD122+ Treg cells, whereas depletion of CD8+ T cells largely abolished the status of long-term allograft survival. Our findings indicate that CD8 + CD122+ Treg cells themselves are resistant to conventional CD40/CD40L and B7/CD28 costimulatory blockade. On the other hand, either CD8 + CD122+ or CD4 + CD25+ Treg cells induced by donor-antigen inoculation and costimulatory blockade is more efficient in suppression than that induced by costimulatory blockade alone, implying that more antigenspecific CD8 + CD122+ or CD4 + CD25+ Treg cells may have been generated by intratesticular inoculation with donor antigens and that both subsets of Treg cells are involved in testicular immune privilege. Mechanisms underlying CD8 + CD122+ Treg suppression of alloreactivity remain to be defined. One of the potential mechanisms by which CD8+ T cells modulate alloimmune responses in a suppression assay is the killing of allogeneic cells or stimulators, thus reducing the immune responses. This may not be the case in our studies as the endogenous CD8 + CD122+ cells are not accelerating skin-allograft rejection but rather prolonging its survival. It is likely that they prolong allograft survival by suppressing alloreactive T cell proliferation or activation through their production of IL-10, as described previously by others. 41 FIGURE 6. Depleting CD8+ T cells abrogates long-term allograft survival induced by intratesticular inoculation and costimulatory blockade. Recipient mice were immunized with donor splenocytes before transplantation and treated with costimulatory blockade on transplantation as described in Figure 1A . In some groups, recipients were treated with depleting anti-CD8 Ab, anti-CD25 Ab, or isotype control Ab. Depleting either CD8+ or CD25+ T cells reversed longterm skin allograft survival induced by preemptive intratesticular inoculation with donor alloantigens and blockade of both CD40/CD40L and B7/CD28 costimulatory pathways. (
